Clinical Trial Update: A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 2, Phase 3]

View source ↗

Summary

A study to determine whether adding fianlimab to cemiplimab improves outcomes versus cemiplimab alone in adults with advanced non-small cell lung cancer (Phase …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cemiplimab (cemiplimab)
• Fianlimab (fianlimab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Advanced Non-Small Cell Lung Cancer | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING